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ABSTRACT
Objective To evaluate the implementation of National 
Institute for Health and Care Excellence antenatal 
hypertension guidelines, to identify strategies to reduce 
incidences of severe hypertension and associated 
maternal and perinatal morbidity and mortality in pregnant 
women with chronic hypertension.
Methods We used a multiple method multisite approach 
to establish implementation of guidelines and the 
associated barriers and facilitators. We used a national 
survey of healthcare professionals (n=97), case notes 
review (n=55) and structured observations (n=42) to 
assess implementation. The barriers and facilitators to 
implementation were identified from semistructured 
qualitative interviews with healthcare professionals (n=13) 
and pregnant women (n=18) using inductive thematic 
analysis. The findings were integrated and evaluated using 
the Consolidated Framework for Implementation Research.
Setting and participants Pregnant women with chronic 
hypertension and their principal carers (obstetricians, 
midwives and physicians), at three National Health Service 
hospital trusts with different models of care.
Results We found severe hypertension to be prevalent 
(46% of case notes reviewed) and target blood 
pressure practices to be suboptimal (56% of women 
had an antenatal blood pressure target documented). 
Women were infrequently given information (52%) 
or offered choice (19%) regarding antihypertensives. 
Women (14/18) reported internal conflict in taking 
antihypertensives and non- adherence was prevalent 
(8/18). Women who were concordant with treatment 
recommendations described having mutual trust with 
professionals mediated through appropriate information, 
side effect management and involvement in decision 
making. Professionals reported needing updates and 
tools for target blood pressure setting and shared 
decision making underpinned by antihypertensive safety 
and effectiveness research.
Conclusions Women’s non- adherence to 
antihypertensives is higher than anticipated. Suboptimal 
information provision around treatment, choice 
of antihypertensives and target setting practices 
by healthcare professionals may be contributory. 
Understanding the reasons for non- adherence will inform 
education and decision- making strategies needed to 
address both clinician and women’s behaviour. Further 
research into the effectiveness and long- term safety of 
common antihypertensives is also required.
BACKGROUND
Hypertension in pregnancy is one of the 
leading causes of maternal mortality world-
wide1 and although mortality is declining in 
the UK,2 women can still experience substan-
tial morbidity from complications such as 
eclampsia and stroke.3 Additionally, peri-
natal mortality remains high, with the UK 
population attributable risk of stillbirth from 
chronic hypertension at 14%4 and around 
half of all neonates born to mothers who have 
had severe hypertension in pregnancy being 
admitted to the neonatal unit.5 The morbidity 
and mortality attributable to hypertension, 
in many cases, may be modifiable through 
optimal use of antihypertensive agents during 
pregnancy.
The National Institute for Health and Care 
Excellence (NICE) hypertension in preg-
nancy guidelines (2010)6 and linked quality 
statements (2013)7 contain a quality state-
ment regarding the provision of information 
on the use of safe antihypertensive medica-
tion in pregnancy and has related guidance 
that recommends discontinuation of tera-
togenic medications such as ACE inhibitors 
or angiotensin II receptor blockers with 
Strengths and limitations of this study
 ► Multiple methodological approaches and an imple-
mentation framework improved the reliability, valid-
ity and generalisability of the study.
 ► Structured observations were carried out using a 
validated tool with high inter- rater reliability.
 ► Women’s medication behaviours were explored in- 
depth using a qualitative interview approach and 
have identified antihypertensive side effects to be a 
factor of non- adherence in pregnant women.
 ► About two- fifths of women who participated in this 
study were from Black, Asian and minority ethnic 
groups, providing a diverse range of voices.
 ► Respondents to the survey were self- selecting 
and may represent a relatively interested group of 
healthcare professionals.
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prescribing of safe alternatives. Any prescribing of alterna-
tive antihypertensive medication should be dependent on 
prepregnancy treatment, side effect profiles and teratoge-
nicity. A second quality statement advocates that women 
taking antihypertensive medication should have a blood 
pressure target (usually of less than 150/100 mm Hg) 
set in pregnancy. All NICE guidelines are underpinned 
by the recommendation of enabling patients to actively 
participate in their care which includes adopting a shared 
decision- making approach to treatment decisions.8
Despite publication of the guideline almost a decade 
ago, the implementation and evaluation of associated 
determinants of uptake have not been nationally evalu-
ated. As a result, targeted strategies to reduce maternal 
and perinatal morbidity (and mortality) resulting from 
severe hypertension remain unidentified. Using the 
Consolidated Framework for Implementation Research 
(CFIR),9 the aim of the study was to evaluate the imple-
mentation of NICE hypertension in pregnancy guidelines, 
to identify strategies to reduce incidence of severe hyper-
tension and associated maternal and perinatal morbidity 
and mortality in pregnant women with chronic hyper-
tension. In many countries, there is a movement toward 
establishing consensus- driven standardised clinical guide-
lines with the aim of improving patient safety and clin-
ical outcomes. While new research continually emerges, 
guidelines are periodically updated and therefore remain 
an appropriate standard for evaluating routine clinical 
practice.10
RESEARCH DESIGN AND METHODS
Study setting and overall methodology
The Chronic Hypertension in pregnAncy iMPlementa-
tION (CHAMPION study) is a multiple methods evalu-
ation of the implementation of the NICE hypertension 
in pregnancy guidelines (2010 and updated in 2013) in 
women with chronic hypertension diagnosed before 20 
weeks.6 7 The study aimed to evaluate the variability in 
implementation of hypertension management practices 
set out in the NICE hypertension in pregnancy guide-
lines (2010).6 As all guidelines should be underpinned by 
the ‘Patient experience in adult National Health Service 
(NHS) services guideline’,8 which includes actively 
involving patient in decisions about their care through 
information provision and shared decision- making, the 
provision of information and women’s involvement in 
decision making was also evaluated. The involvement of 
women in decision making was considered integral to the 
implementation study because successful hypertension 
management strategies involve the adherence to, along-
side the prescribing of, antihypertensive medication.
Implementation was assessed through multiple 
methods: an online national survey of healthcare profes-
sionals, designed to describe general trends in guide-
line implementation; through review of the maternity 
case notes of women who had already given birth, a 
method that assessed the documentation of hypertension 
management occurrence in each woman’s maternity 
record. Aspects of care that would not normally be docu-
mented or are more difficult to capture, such as in- con-
sultation discussions and occurrence of shared decision 
making were assessed through observations carried out by 
a midwife researcher (RW). The evaluation of the barriers 
and facilitators to implementation of NICE guidelines 
was assessed through qualitative interviews (with the same 
women and healthcare professionals who participated in 
the observation phase) using the CFIR. The study draws 
on CFIR as a theoretical framework to guide data collec-
tion, analysis and interpretation. The CFIR framework 
specifically evaluates five key domains that influence 
implementation; each domain has several subgroups to 
it, although only those relevant to this study have been 
identified. These include the intervention characteristics 
(the NICE guidelines), the outer context (the pregnant 
women), the inner context (NHS maternity services), 
individual context (the healthcare professionals) and the 
process of implementation (potential strategies).
Implementation of guidelines was assessed between 
November 2017 to December 2018 at three NHS Trusts 
with typical configurations of services for pregnant 
women with hypertension in the UK. Hospital Trust 1 was 
a tertiary city centre hospital with a newly formed specialist 
service that included consultant obstetricians, obstetric 
physicians and midwives who provided antenatal and 
intrapartum care to women with chronic hypertension 
within a specialist clinic; Hospital Trust 2 was a suburban 
district general hospital with a consultant- led antenatal 
clinic with antenatal midwives alongside providing care to 
women with a variety of pre- existing medical conditions; 
and Hospital Trust 3 had both a tertiary and a semi- rural 
hospital with a joint obstetric and physician led clinic and 
usual community- based midwifery care. No adjustment 
for clustering was required as no statistical comparison 
between sites was made. The NICE hypertension in preg-
nancy guidelines (2010)6 had been adopted into local 
clinical guidelines at all three participating NHS Trusts for 
several years prior to the assessment of implementation.
The National Survey
The implementation of evidence- based practices for the 
management of hypertension in pregnancy was assessed 
through self- reporting using an online survey (survey-
gizmo/s3). We embedded questions relating to the 
uptake of the NICE hypertension in pregnancy guide-
lines (2010)6 using the 'template for intervention descrip-
tion and replication' (TIDieR) framework.11 The 12- item 
TIDieR checklist (brief name, why, what (materials), 
what (procedure), who provided, how, where, when and 
how much, tailoring, modifications, how well (planned), 
how well (actual) is an extension of the Consolidated 
Standards of Reporting Trials 2010 statement (item 5) 
and the Standard Protocol Items: Recommendations 
for Interventional Trials 2013 statement (item 11). 
Although the emphasis of the TIDieR checklist is on 
reporting interventions for trials, the checklist was used 
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as a basis for this survey (but not as a reporting guide-
line) as it is also intended to apply across all evaluative 
study designs.11 There is no single database of health-
care professionals’ email addresses so national organi-
sations including British Maternal and Fetal Medicine 
Society, Macdonald UK Obstetric Medicine Society and 
Royal College of Midwives were asked to email the survey 
(April to September 2018) to their members. No fee was 
charged as members’ contact details were not shared with 
us and as a result the response rate could not be calcu-
lated. Ninety- seven healthcare professionals from 69 
NHS Trusts responded, including 53 consultant obstetri-
cians (55%), 16 doctors in training (16%), 22 specialist 
midwives (23%) and 6 community midwives (6%) (full 
copy of survey questions shown in online supplemental 
material 1).
Case-notes review
The implementation of NICE guidelines (2010)6 was 
also assessed through review of 100 maternity case notes 
of women with chronic hypertension identified from 
the electronic maternity records (32, 33, 35 women per 
Trust). At two of the Trusts, all women who had given 
birth in 2017 were included, whereas at the other Trust 
all women who had given birth over the final 3 months of 
2017 were included as this third Trust had approximately 
four times the number of women with chronic hyperten-
sion per annuum. In the UK, many women have abridged 
electronic maternity records and extensive handheld 
paper notes that are carried throughout pregnancy but 
are stored thereafter in the hospital. Both the electronic 
system and paper notes were obtained in the case notes 
review of care. Due to use of varying terms for hyperten-
sion on the electronic system, some women identified 
for case- note review were excluded as they did not have 
chronic hypertension when the full case notes were exam-
ined. Other reasons for exclusion included early miscar-
riage and transfer of care to another maternity unit. Data 
extraction based on the NICE hypertension in preg-
nancy guidelines (2010)6 was completed by two midwife 
researchers (RW and HW), and minor discrepancies 
were resolved by discussion between the two researchers. 
It was not necessary to include a third reviewer as no 
major discrepancies were identified. Unclear or absent 
documentation including height, weight and body mass 
index (BMI) or antenatal blood pressure recordings 
was recorded as missing data. Severe hypertension was 
defined as systolic blood pressure greater than or equal 
to 160 mm Hg systolic or diastolic blood pressure greater 
than or equal to 110 mm Hg. For the assessment of BP 
targets, the quality statement related to documentation of 
a target (or not), not to the specific numerical thresholds 
chosen.
Observations
Forty- two antenatal appointments involving 23 women 
with chronic hypertension and their respective doctors 
(nine) and midwives (five) were observed by a midwife 
researcher (RW) at the three NHS Trusts. Women with 
chronic hypertension were purposively sampled at their 
first obstetric antenatal appointment and, based on the 
availability of the midwife researcher, were approached 
consecutively along with their respective healthcare 
professionals until data saturation occurred. Staff and 
women gave written informed consent. Two women 
declined recruitment to the study. During observations, 
data about antenatal care provision were recorded using 
the Calgary- Cambridge communication guide12 chosen 
for validity in relation to the research question, and its 
high inter- rater reliability. For example, offering choice 
is a subsection of shared decision making and is defined 
as ‘encourages patient to make choices and decisions to 
the level that they wish’. Attainment of each section and 
subsections was established through the analysis of all 42 
appointments using descriptive statistics.
Semistructured interviews
Views about barriers and facilitators to implementation 
of evidence- based guidelines were collected from nine 
doctors and four midwives who were providing antenatal 
care for women with chronic hypertension. The inter-
views were carried out by a midwife researcher (RW) 
following informed consent and took place in privacy 
away from the clinical setting. The interviews were audio 
transcribed, coded and thematically analysed using 
inductive reasoning.13 The codes generated formed small 
themes which were organised into the CFIR evaluation 
guide.14 As formal implementation strategies had not 
been adopted beyond producing local guidance, inter-
viewees were asked how they thought they could improve 
the implementation in the future.
Semistructured interviews with 18 women recruited 
for antenatal observations were carried out in the third 
trimester with informed consent. Women were asked 
about their antenatal care experiences using an inter-
view schedule which reflected the concepts from the 
International Consortium for Health Outcome Measure 
(ICHOM) maternity standards sets15 which include 
women’s overall satisfaction with their care during preg-
nancy; satisfaction with information provision and their 
relationships with their care providers (see online supple-
mental material 2). ICHOM standards are internationally 
recognised measures that evaluate health outcomes that 
are important to patients (or pregnant women) and are 
used to improve local healthcare and compare outcomes 
internationally. The closed survey questions were turned 
into open ended questions to explore in- depth the 
quality of antenatal care provided. The interviews were 
carried out by a midwife researcher (RW) and took place 
away from the clinical setting, with assurance that discus-
sions would not be shared with healthcare professionals 
and that participation or non- participation would not 
influence their care. The interviews were audio tran-
scribed, coded and thematically analysed using an induc-
tive approach. Women’s experiences were analysed to 
improve understanding of their antenatal care needs, 
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which included how their hypertension was managed and 
the barriers and facilitators to the uptake of antihyperten-
sives in pregnancy.
Data analysis
The quantitative and qualitative data were analysed sepa-
rately before being integrated. Descriptive analysis and 
summary statistics were used for the quantitative data. 
The semistructured interviews were thematically anal-
ysed by researchers (RW, JS and LC) using inductive 
techniques and typically lasted between 30 and 60 min.16 
The multiple methods data were integrated and analysed 
using the CFIR evaluation framework.14 This included 
probing the inductively generated qualitative themes 
that related to implementation. The interpretation of 
the intervention constructs (characteristics, the inner 
and outer settings, the individual characteristics and the 
implementation processes) was carried out initially by the 
midwife researcher (RW) who collected the data, then 
with a second and third researcher (LC and JS) inter-
preting and discussing final interpretation of integrated 
data. Rigour was maintained through member reflec-
tion, attention to interview and transcription quality and 
systematic analysis. Rigour was improved using multiple 
data sources, a comprehensive integration framework 
(CFIR) and a multiple methods integration checklist.17 
Researchers were aware of, and sensitive to, the way in 
which their roles as midwives and doctor may have shaped 
the generation and analysis of the qualitative data.
Patient and public involvement
A patient participant involvement (PPI) group consisting 
of women with experience of hypertension in pregnancy 
(n=7) and a maternity voices partnership group (n=15) 
provided feedback on the design of the study, research 
questions and outcome measures. The views of Black, 
Asian and minority ethnic women were purposively 
sought as they are disproportionately represented in the 
chronic hypertension in pregnancy population. PPI focus 
groups discussed what aspects of care were important to 
evaluate, this included the information women were given 
during pregnancy and whether women were involved in 
decisions about their care. They also provided construc-
tively critical feedback on the patient information leaflets 
and consent forms.
RESULTS
Antenatal care for women with chronic hypertension 
was provided by consultant obstetricians and midwives at 
all three hospitals. In two of the hospitals, women with 
chronic hypertension had designated midwives attached 
to the obstetric clinic. Approximately one- third of those 
recruited to the study had a BMI over 30 kg/m2, approx-
imately one- third were over the age of 35 and approxi-
mately two- fifths were of Black, Asian and minority ethnic 
backgrounds (shown in online supplemental material 3). 
Hospital Trust 1 had four times the population of women 
with chronic hypertension compared with the other two 
units, comprising a large black minority ethnic popu-
lation (many with associated comorbidities). Perinatal 
outcomes from the 55 pregnancies identified for case 
notes review showed that just under half of the women 
(46%) developed severe hypertension and that one in six 
babies were admitted to the neonatal unit (16%) (shown 
in online supplemental material 4). At all three hospitals 
medical history of women with chronic hypertension was 
inaccurate in the maternity records system and episodes 
of severe hypertension were recorded only in hand- 
written notes.
Implementation of NICE hypertension in pregnancy 2010 
guidelines and 2013 quality standards
Setting a blood pressure target (quality statement 3)
Both the survey and the case notes review found the prac-
tice of setting an antenatal target blood pressure to be 
variable (table 1). Just over half of women with chronic 
hypertension had a target blood pressure documented in 
maternity notes (44% did not) yet substantial variation in 
practice between hospitals existed. At Hospital Trust 1, 
77% of women had a target blood pressure documented 
in pregnancy compared with 23% and 38% at Hospital 
Trusts 2 and 3 respectively (online supplemental mate-
rial 5). While it is possible that undocumented discus-
sions occurred during consultations, which could not be 
extracted from case note review, such discussions would 
not be accessible on a longer- term basis to the woman 
or to other healthcare professionals involved in her care. 
The survey results support the case notes review findings 
as only a third of healthcare professional respondents 
reported always setting a target. The practice of undocu-
mented ‘unshared’ target setting was identified through 
case notes review. Evidence of blood pressure targets 
being used by healthcare professionals but not shared 
with the woman and other professionals (‘unshared’) was 
frequently found. In about three- quarters of cases where 
the target blood pressure was unshared, and the blood 
pressure rose above systolic 150 mm Hg and or diastolic 
100 mm Hg action was taken by professionals to lower it. 
Action was defined as making changes to blood pressure 
treatment, changing frequency of blood pressure moni-
toring or frequency of appointments (table 1).
Antihypertensive information provision, decision 
making and prescribing (quality statement 1 and associ-
ated guidance)
Variation in practice regarding first- line and second- 
line prescribing was identified through both the notes 
review and survey (table 1). In both, labetalol was the 
most commonly prescribed first line and nifedipine 
the most commonly used second- line antihyperten-
sive agent; nevertheless, in about half of the case notes 
reviewed labetalol was not the first line antihypertensive 
prescribed. First line prescribing is not always exclusive 
as it may vary by ethnicity (eg, some doctors use labetalol 
as first line for many women, but nifedipine for Black 
women, in line with national guidelines for prescribing 
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outside of pregnancy)18 which may explain the variation 
in prescribing practice that existed (online supplemental 
material 5). Variation may also be explained by clinician 
preference or medication preference identified through 
shared decision making.
Information provision about antihypertensive prescribing
Across all three Trusts, 52% (41/79) of the time the 
correct type and amount of information was provided 
during the consultation (measured using the Calgary- 
Cambridge Guide). Visual techniques such as drawing 
or using charts to provide information occurred during 
consultation in 14% (3/21) of cases.
Achieving a shared understanding: incorporating the woman’s 
perspective
Of the survey respondents 96.9% strongly agreed or 
agreed that involving women with chronic hypertension 
Table 1 Variation in implementation of evidence- based care evaluated through a national survey of obstetricians and 
midwives and women’s case notes review at three representative NHS Trusts
Care quality indicators National survey n=97 (%) Case notes review n=55 (%)
Blood pressure target setting (QS3)
  Target blood pressure ‘always’ set 36 (37.1)
  Target blood pressure ‘almost always’ set 36 (37.1)
  Target blood pressure ‘never’ set 1 (1.0)
  Target blood pressure not applicable (midwife) 24 (23.3)
  Target blood pressure set at first opportunity
  (whichever first: booking or commencement of AHT)
– 9 (18.0)
  Target blood pressure not documented 26 (43.6)
Systolic target blood pressure
  <160 mm Hg 8 (8.2)
  <150 mm Hg 89 (91.8) 2 (7.4)
  ≤140 mm Hg   27 (49.0)
Diastolic target blood pressure
  <100 mm Hg 94 (96.9) 2 (7.4)
  ≤90 mm Hg 27 (49.0)
  Action taken to reduce blood pressure if above 150/100 mm Hg 13/17 (76.5)
Safe antihypertensive prescribing (linked to QS1)
  ACEi and ARBs cessation
   On ACEis or ARBs at antenatal booking appointment 4 (7.3)
   Stopping ACEi or ARBs at first app if woman on either
   Always 57/86 (66.3) –
   Almost always 27/86 (31.4) –
   ACEis or ARBs stopped at first obstetric appointment 4/4 (100.0)
  First- line AHT prescribing (non- exclusive)
   Labetalol 85 (87.6) 28 (50.9)
   Nifedipine 32 (33.0) 9 (16.4)
   Methyldopa 29 (29.9) 8 (14.5)
   Other, for example, amlodipine 2 (2.1) 4 (7.3)
   None – 6 (10.9)
  Second line AHT prescribing (non- exclusive)
   Nifedipine 79 (81.4) 9 (16.4)
   Methyldopa 60 (61.9) 4 (7.3)
   Labetalol 38 (39.2) 3 (5.4)
   Amlodipine 37 (38.1) 2 (3.6)
   Doxazosin 23 (23.7) 0 (0.0)
   Other 5 (5.2) 0 (0.0)
   None – 37 (67.3)
ACEi, ACE inhibitors ; AHT, Anti- hypertensive; ARBs, Angiotensin II receptor blockers; NHS, National Health Service.
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in management plans during pregnancy was important. 
However, when asked to give examples of how they 
involve women, only 4.3% identified discussing risks and 
benefits of treatment choice and 10% of respondents 
identified that women could be involved in plans about 
antihypertensive prescribing. The observations in the 
three hospital trusts found that 43% of the time (41/96) 
shared decision making occurred and 19% of women 
(3/16) were offered a choice regarding their hyperten-
sive plans (including choice of antihypertensive).
Barriers and facilitators to implementation (CFIR)
Intervention characteristics (evidence and guideline)
All professionals interviewed, except one, saw value in 
having national guidance and understood that the local 
guidelines had been adapted from the 2010 national guide-
line.6 Midwives relied more on local guidelines compared 
with obstetricians who referred more commonly to NICE 
guidelines. Some of the medical professionals had been 
involved in the development of an NICE guideline and 
were aware of the strengths and limitations of producing 
evidence- based guidelines in terms of the need for timely 
updating. Professionals described difficulties in creating 
guidelines where there is a paucity of robust data as is 
sometimes the case in maternity care. Weak, out of date 
or absent evidence influenced doctors’ decisions not to 
implement guidelines. Some doctors described the weak-
nesses in the evidence underpinning the hypertension 
guidelines and described relying more on recent research 
compared with older national guidelines (table 2). The 
professionals identified that further research is neces-
sary to support evidenced- based national guidelines 
(figure 1).
Inner setting (organisation structure and culture)
The most frequently cited barriers to implementing high 
quality care for women with chronic hypertension were 
linked to the structure and organisation of antenatal care. 
Interviewees reported that a lack of consensus and guid-
ance exists relating to models of care (such as whether 
specialist services would improve outcomes through 
better implementation) and pathways of care (such as 
frequency of blood pressure and medication reviews) 
(table 2). Evidence- based recommendations on models, 
and pathways of care, were identified as future facilita-
tors to providing optimal antenatal care (figure 1). While 
most healthcare professionals initially described the 
uptake of the guidelines as a clinical priority during the 
interviews, clinicians identified difficulty with keeping up 
with recommendations and using them alongside clinical 
judgement as barriers to implementation (table 2).
Healthcare professionals considered the absence of 
written information a barrier to the uptake of antihyper-
tensives in women with hypertension (table 2). A degree 
of paternalism exists in relation to involving women in 
decisions about their care. In principle, clinicians would 
like to involve women in decision making, yet they gave 
many examples of situations where they would exercise 
restraint in doing so (table 2). Education and tools to 
support shared decision making were identified as facili-
tators to optimising antenatal care for women with hyper-
tension (figure 1).
Characteristics of individuals (beliefs, knowledge and self-efficacy)
Interview analysis identified doctors’ and midwives’ 
knowledge and beliefs as the second most frequently 
cited barrier and facilitator to the implementation of 
hypertension management guidelines (table 2). There 
existed confusion about whether the guidelines sanc-
tion one antihypertensive medication over another for 
the management of chronic hypertension and if so, what 
evidence was used to support this. Likewise, confusion 
about blood pressure targets was described frequently 
as outcomes from a recent randomised controlled trial 
superseded the predated national guidelines (table 2). 
While midwives experienced less self- efficacy than the 
doctors, doctors still experienced difficulties in this area. 
They occasionally described the women’s beliefs and 
views as a barrier to implementing the recommendations 
(table 2).
Outer setting (women’s views and experiences)
The quality of antenatal care experience was affected by 
women’s internal conflict. There was also a high degree 
of variability in medication adherence (defined as, a 
blanket term factoring the extent to which patients’ drug 
dosing histories conform, or not, to their corresponding 
prescribed drug dosing regimen)19 and concordance 
(defined as, an agreement after negotiation between a 
woman and a healthcare professional that respects the 
beliefs and wishes of the woman in determining whether, 
when, and how medicines are to be taken).20 Analysis 
identified that women require quality information about 
antihypertensives and their side effects, blood pressure 
ranges in pregnancy, as well as support to actively partici-
pate in decision making.
Internal conflict
The majority (14 of 18) of women experienced internal 
conflict relating to the management of their hyperten-
sion during pregnancy, defined as a state of uncertainty 
about the course of action to take often in relation to 
making choices involving risk or uncertainty of outcomes 
(8) (figure 2A). The causes of internal conflict were iden-
tified as a lack of information provision, poorly managed 
side effects, women’s personal beliefs and factors relating 
to the healthcare professional (table 3).
Concordance
All women identified as concordant with healthcare 
professional management plans described being 
adherent to their antihypertensives. Facilitators to 
concordance included trust in the healthcare profes-
sional, mediated through information about safety of 
antihypertensives in pregnancy, knowledge about target 
blood pressure in pregnancy hypertension, acknowl-
edgement of medication side- effects and a positive 
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interaction with the healthcare professional (including 
communication and approach to decision making) 
(figure 2B).
Adherence
Internal conflict was an important determinant of non- 
adherence (figure 2A) as only the women who expressed 
Table 2 Barriers to healthcare professional’s implementation of hypertension in pregnancy guidelines, based on Consolidated 
Framework for Implementation Research (CFIR) implementation themes
CFIR 
implementation 





17 AHT prescribing; 
target setting
 ► ’I think the fact that it says use labetalol first line is not what we do, I don’t 
believe the evidence for labetalol being better than methyldopa is there.’H
 ► ‘We can’t get away from the fact that there aren’t the source data there to 
make evidence- based guidelines.’B
 ► ’So, I kept a close track of what was happening with the CHIPS study…I got a 










 ► ‘I don’t think we have a hand- out for, to give to hypertensive women about 
hypertension in pregnancy’.L
 ► ‘We don’t have a dedicated hypertension clinic here. So, most of these women 
will get seen in general antenatal clinic’.I
 ► ’You have people coming in three times weekly or something for their blood 
pressure, really? And other people who perhaps aren’t being seen enough’.I
Relative priority 26 Guidelines; self- 
study; beliefs; 
experience
 ► ’Well actually I don’t even know what the NICE guidelines are for hypertension, 
I’m not a… as my colleagues will tell you, not a huge fan of NICE, in many 
ways.’L
 ► ‘I’m not just interested in guidelines; I’m interested in people’s clinical 
experience…and that feel.’C







urgent and non- 
urgent
 ► ‘Doctors… see it as patients not doing what they’re told’.A
 ► ‘I think that there’s a balance to be had between involving women in the 
decisions, vs, them coming for expert recommendations’F
 ► ’If I have a clinical situation where I want to start antihypertensives because 
she’s got a dangerously high blood pressure, then that discussion is inevitably 
truncated.’B
Individual characteristic
Beliefs about the 
intervention
35 AHT medication; 
AHT safety and 
side effects; 
target setting
 ► ‘National guidelines do not sanction any particular antihypertensive, or that 
the, the drug licenses do not sanction any particular antihypertensive’B
 ► ’I think that might be something we’re not quite as good at as we should be 
about defining a target for women….I suspect it’s something we don’t really 
document and clarify’H





 ► ‘I think sometimes women don’t necessarily want to make the decision’D
 ► ‘There’s a lot of ‘mumsnet’….and I would say they take a, that advice just as 
seriously as they do the advice that we give them here.’C
Process of implementation
Engaging people 
and process of 
implementation





 ► ‘Awareness for people, if you’re a busy jobbing healthcare practitioner, 
keeping up to date with each new area’H
 ► ‘Practical toolkits to help with that consultation’B
 ► ‘Evidenced based information having it more readily available for patient’D
Opinion leaders; 
Champions;




 ► ’I find as a midwife sometimes you’re a bit powerless, you know what the 
guidelines are, but depending on the doctor you’re working with, tends to 
be the influencing factor on the decisions that are made… so it seems to 
be clinician- based guidelines sometimes, rather than the trust or national 
guidelines’D
LettersA- M represent the healthcare professionals interviewed.
NICE, National Institute for Health and Care Excellence.
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internal conflict reported non- adherence to antihyper-
tensive medication. Around half (8 of 18) the women 
interviewed described non- adherence to prescribed 
antihypertensives at some point during pregnancy with 
three women non- adherent at the time of interview (third 
trimester). However, 9 of 14 women describing internal 
conflict were adherent at the time of interview which was 
mediated by the ‘responsibility of motherhood’ rather 
than concordance with the hypertension management 
plan (figure 2B).
Process of implementation (implementation strategies)
All three Trusts had a consultant obstetrician who led the 
care of women with chronic hypertension and could be 
considered the opinion leader. Two of three Trusts had 
a named midwife or team of midwives who specialised in 
the care of these women and were potential champions. 
However, influencers and champions were not always 
utilised to support guideline implementation. Further, as 
implementation of the guidelines had not been audited 
in any of the Trusts, although some outcome data was 
routinely collected and analysed, opportunities to address 
unwanted variability were being missed. These findings 
are supported by the national survey which found only a 
quarter of the Trusts collected and analysed the outcomes 
of women with chronic hypertension in pregnancy.
DISCUSSION
Women in this study (14/18) reported conflict relating 
to the uptake of prescribed antihypertensives in preg-
nancy and in many cases (8/14) internal conflict resulted 
in non- adherence. The most commonly cited reasons 
for conflict were lack of information provision, the side 
effects experienced from the medication, beliefs about 
safety of medication and uncertainty about normal blood 
pressure ranges in pregnancy. Adherence to antihyper-
tensives in conflicted pregnant women was mediated 
Figure 1 Interpretation of integrated analysis: a strategy for improved implementation of evidence- based hypertension in 
pregnancy management. AHT, Anti- hypertensive; CHT, Chronic hypertension; HCP, healthcare professional.
Figure 2 (A) Women’s adherence and concordance with prescribed antihypertensives. Numbers 1–18 represent interviewed 
women and their experiences of antihypertensive prescribing during pregnancy. Women who experienced a change in their 
adherence or in the reporting of internal conflict are plotted more than once in different bubbles. (B) Facilitators of women’s 
adherence and of concordance. HCP, healthcare professional.
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through a responsibility to motherhood rather than 
through a trusting partnership with healthcare profes-
sionals (supported by information provision, manage-
ment of side effects and relational factors) as found in 
concordant adherent women. Despite this, our findings 
demonstrated that optimal information provision about 
antihypertensives and shared decision making occurred 
infrequently during antenatal consultations. Our findings 
also illustrated that the implementation of blood pressure 
target setting was suboptimal as a result of ‘unshared’ 
or undocumented target setting and in some cases an 
absence of target setting.
A major strength of the study is the recruitment of Black, 
Asian and minority ethnic women to both the research 
(40%) and in the PPI planning stage as these women are 
disproportionately represented in the chronic hyperten-
sion in pregnancy population. A further strength is the 
use of multiple methodological approaches and an imple-
mentation framework in order to improve reliability, 
validity and generalisability. However, results from the 
national survey may overstate compliance with national 
guidance. The survey was sent out to healthcare profes-
sionals from professional organisations; respondents 
were, therefore, self- selecting and may represent a rela-
tively interested group of healthcare professionals. The 
non- response rate is also unknown. The structured obser-
vations were carried out using a validated tool with high 
inter- rater reliability.12 However, the observations were 
carried out by one midwife researcher which may affect 
the validity of the findings. Finally, the purposive sampling 
of healthcare professionals providing routine antenatal 
care for women with chronic hypertension resulted in a 
focus on lead carers (consultant obstetricians, obstetric 
medicine specialists and named midwives) being inter-
viewed, rather than doctors in training and midwives in 
acute areas such as the maternity assessment unit.
The emergence of implementation science in recent 
years has identified that a gap between research findings 
and clinical practice exists, and that clinical guideline 
production does not ensure evidence- based practices are 
routinely adopted.21 A recent study in British Colombia 
evaluated the implementation of recently published 
pregnancy hypertension guidelines and its associated 
effect on maternal and perinatal outcomes.22 Following 
guideline dissemination the study reported a fall of about 
a third in combined adverse maternal health outcomes 




conflict Frequency Codes Representative answer
Information 30 Medication (choices, 
dose, effectiveness, 
safety, interactions); 
severity of HTN; effect 
of HTN on pregnancy
’(I wanted to know) how safe it is, about the dosage, about the, taking the 
med-, this medication, about the side- effects and so and so and so, if they 
think any other option for me, or if this medication is not working, what will 
be the other option for me’J
‘He was, you still need to carry on with your ramipril. I know I can’t take it. It 
says in the leaflet not to take once you’ve hit 6 weeks, you need to stop. So, 
he was like oh, and then he phoned here, and he said oh well just take what 
you took before’H
Side effects 21 Maternal side effects; 
fetal side effects; 
Interactions; allergies; 
choices
‘They gave me first three, twice a day, then I was so giddy where I couldn’t, 
if I take, I had to sleep all day for 2 days…Then I complained, but they still 
say to still take tablet.’I
’I’m on 18 pills a day, I do worry a bit about how they kind of potentially 
interact with each other and affect the baby’F




’I felt like I had to justify why I wasn’t taking my tablet, which to me didn’t 
seem right, ‘cause if it, if my blood pressure was normal, and I took a tablet, 
surely my blood pressure then would be low?’Q
‘cause everything I take my baby takes. So, it’s like, what happens if my 
child comes out and then they’re addicted to something, or they’re high- 
strung because of something, or they’re really moody and they’re crying all 
the time because of the medicine I’ve had to take for the past 4 months’L
HCP factors 17 Continuity; listening 
to women; explaining 
regimes, mutual trust; 
communication
’My issue has been where I’ve seen somebody who doesn’t know the 
history, and typically they are a more junior doctor, and typically they are 
ticking a box and following a flow chart….the doctor said, you know, we’re 
going to come to an agreement together but there was absolutely no 
discussion, she had no interest in what I had to say.’K
External factors 7 Family and friends; 
internet; access to 
services
’My dad had been on beta blockers, which is what labetalol is, when he 
was younger, and he found, he was very ill on them, so he gave me a really 
negative impression of them’P
LettersA- R represent the pregnant women interviewed.
AHT, Anti- hypertensive; CFIR, Consolidated Framework for Implementation Research; HCP, healthcare professional; HTN, Hypertension.
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(3.1%–1.9%) but did not report a significant reduction 
in adverse perinatal outcomes.22 However, the wanted 
and unwanted variability in guidance uptake was not 
reported and the underlying mechanisms that influenced 
outcomes is not described. Our study uses an implemen-
tation framework by which variability in the implemen-
tation of existing guidelines could be described and 
mechanisms that support and hinder their uptake can 
be analysed, uniquely identifying strategies to improve 
the uptake of guidance and reduce maternal and fetal 
morbidity. Critically, although the NICE hypertension 
in pregnancy guidelines6 have been recently updated, 
the core hypertension management recommendations 
remain unchanged, as do the quality statements. There-
fore, the findings of this study remain important and rele-
vant to those wanting to improve implementation.
The study also adds to the small body of antihyper-
tensive adherence in pregnancy research that has 
found antihypertensive side effects are a determinant 
of non- adherence. One recent randomised controlled 
trial identified 11% of those included in randomisation 
discontinued the antihypertensive due to side effects.23 
Through the qualitative interview approach that enabled 
in depth exploration of women’s medication behaviours, 
our study found about 40% of all women did not adhere 
to their prescribed antihypertensives at some point 
during pregnancy. This number compared more similarly 
to an internet- based study of 210 pregnant women under-
taken in Europe, America and Australia which identified 
a 32.9% non- adherence rate in women taking cardio-
vascular medications in pregnancy.24 These findings are 
supported by similar smaller questionnaire- based studies 
of pregnant women’s medication adherence.25 26 Our 
study may have identified higher rates of non- adherence 
due to the nature of qualitative interviewing that explore 
in- depth women’s experiences and therefore unpick 
medication behaviours in a way that quantitative studies 
cannot.
Women’s adherence to antihypertensives in pregnancy 
was found to be suboptimal, and strategies to improve 
adherence are likely to reduce incidences of severe 
hypertension and prevent associated morbidity (and 
mortality).27 These include improved information provi-
sion about antihypertensives and blood pressure targets 
as well as embedding shared decision making into prac-
tice. Improvements in target blood pressure setting prac-
tices overall are also likely to reduce incidences of severe 
hypertension and prevent associated morbidity (and 
mortality).3 5
This study adds to the body of research that already exists 
outside of pregnancy which demonstrates that implemen-
tation of guidelines is not optimally achieved through the 
process of diffusion.21 Although there was some evidence 
that some aspects of implementation were improved by 
having a specialist service for hypertension, this is likely to 
be most easily justified in areas where there is a high prev-
alence of chronic hypertension. Therefore, strategies to 
improve implementation in wider settings are required. 
Professionals require guideline updates, implementa-
tion toolkits (to improve target blood pressure setting 
practices, standardised information about antihyperten-
sives and in consultation aids) as well as support to have 
better conversations with their patients about medication 
choices and to improve the involvement of the women in 
the decision making. Professionals also need to buy into 
the evidence that underpins the guidance. Maternal and 
perinatal outcomes, which includes episodes of severe 
hypertension, should be collected annually, and used to 
support informed discussions about optimising antenatal 
care for this group of women.
Further research into the effectiveness and long- term 
safety of common antihypertensives in pregnancy and 
breast feeding to support evidenced- based guidelines 
is required.28 Future research may also wish to evaluate 
strategies to reduce women’s conflict regarding their anti-
hypertensive use in pregnancy and establish the effect 
of interventions on maternal concordance and health 
outcomes. However, without further evidence relating to 
the safety and effectiveness of common antihypertensives 
it is unclear if further reductions in maternal and fetal 
morbidity can be achieved through prescribing prac-
tices. Future research should also focus on active imple-
mentation of blood pressure target setting and pathways 
for those with outside of target blood pressure readings. 
This is likely to reduce morbidity as target blood pressure 
setting in pregnancy has been shown to reduce incidences 
of severe hypertension.3 5 Policy- makers may also wish to 
consider further studies that identify effective models and 
pathways of care for reducing adverse perinatal outcomes 
within the context of pregnancy hypertension.
CONCLUSION
Maternal and neonatal morbidity resulting from severe 
hypertension in pregnancy is prevalent.1 4 5 This evalu-
ation of the implementation of the NICE hypertension 
in pregnancy guidelines (2010)6 addresses strategies to 
reduce the number of episodes of severe hypertension 
and has identified suboptimal target setting practices, 
poor information provision for pregnant women and vari-
ability in prescribing practices. Women’s non- adherence 
to antihypertensives is higher than previously reported 
and this is likely to be contributing to adverse perinatal 
outcomes. Analysis of the domains that influence imple-
mentation of the guidelines have identified that educa-
tion and decision- making strategies are needed to address 
both clinician and women’s behaviour. Further research 
into the effectiveness and long- term safety of common 
antihypertensives is also required.
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